You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

Details for Patent: 11,058,667


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 11,058,667 protect, and when does it expire?

Patent 11,058,667 protects ENTRESTO and is included in one NDA.

This patent has sixteen patent family members in fourteen countries.

Summary for Patent: 11,058,667
Title:Sacubitril-valsartan dosage regimen for treating heart failure
Abstract: The present invention relates to sacubitril-valsartan dosage regimens for the treatment of heart failure in a patient.
Inventor(s): Rizkala; Adel Remond (East Brunswick, NJ), Shi; Victor Chengwei (Mendham, NJ), Chen; Fabian (Englewood Cliffs, NJ)
Assignee: Novartis AG (Basel, CH)
Application Number:15/572,399
Patent Claim Types:
see list of patent claims
Use; Compound;

Drugs Protected by US Patent 11,058,667

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novartis Pharms Corp ENTRESTO sacubitril; valsartan TABLET;ORAL 207620-001 Jul 7, 2015 AB RX Yes No ⤷  Sign Up ⤷  Sign Up TREATING CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION IN PATIENTS NOT TAKING AN ACE INHIBITOR OR AN ARB OR PREVIOUSLY TAKING LOW DOSES OF THESE AGENTS, BY TITRATING UP FROM HALF THE USUALLY RECOMMENDED STARTING DOSE ⤷  Sign Up
Novartis Pharms Corp ENTRESTO sacubitril; valsartan TABLET;ORAL 207620-002 Jul 7, 2015 AB RX Yes No ⤷  Sign Up ⤷  Sign Up TREATING CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION IN PATIENTS NOT TAKING AN ACE INHIBITOR OR AN ARB OR PREVIOUSLY TAKING LOW DOSES OF THESE AGENTS, BY TITRATING UP FROM HALF THE USUALLY RECOMMENDED STARTING DOSE ⤷  Sign Up
Novartis Pharms Corp ENTRESTO sacubitril; valsartan TABLET;ORAL 207620-003 Jul 7, 2015 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up TREATING CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION IN PATIENTS NOT TAKING AN ACE INHIBITOR OR AN ARB OR PREVIOUSLY TAKING LOW DOSES OF THESE AGENTS, BY TITRATING UP FROM HALF THE USUALLY RECOMMENDED STARTING DOSE ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 11,058,667

PCT Information
PCT FiledMay 09, 2016PCT Application Number:PCT/IB2016/052633
PCT Publication Date:November 17, 2016PCT Publication Number: WO2016/181284

International Family Members for US Patent 11,058,667

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Cyprus 1126036 ⤷  Sign Up
Denmark 3294283 ⤷  Sign Up
European Patent Office 3294283 ⤷  Sign Up
European Patent Office 4212152 ⤷  Sign Up
Spain 2945866 ⤷  Sign Up
Finland 3294283 ⤷  Sign Up
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.